Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virginia Fisher

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
The Prostate|March 14, 2022
Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancerEmmanuel S Antonarakis, Marni Tierno, Virginia Fisher, et al.
BMC Genetics|September 27, 2018
The challenge of detecting genotype-by-methylation interaction: GAW20Mariza de Andrade, E Warwick Daw, Aldi T Kraja, et al.
JCO Clinical Cancer Informatics|March 17, 2022
Natural History of Human Epidermal Growth Factor Receptor 2-Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical PracticeCarsten Schröder, Craig Gower-Page, Irmarie Reyes-Rivera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast CarcinomaHope S Rugo, Kira Raskina, Alexa B Schrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2022
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate CancerUmang Swami, Ryon P Graf, Roberto H Nussenzveig, et al.
European Urology|October 30, 2021
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate CancerRyon P Graf, Virginia Fisher, Joaquin Mateo, et al.
JAMA Network Open|March 31, 2022
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate CancerRyon P Graf, Virginia Fisher, Janick Weberpals, et al.
Cancer Discovery|October 31, 2020
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor ResponseMeagan Montesion, Karthikeyan Murugesan, Dexter X Jin, et al.
HGG Advances|December 26, 2022
Whole-exome sequence analysis of anthropometric traits illustrates challenges in identifying effects of rare genetic variantsKristin L Young, Virginia Fisher, Xuan Deng, et al.
Frontiers in Genetics|November 29, 2023
Gene-educational attainment interactions in a multi-population genome-wide meta-analysis identify novel lipid lociLisa de las Fuentes, Karen L Schwander, Michael R Brown, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
The Prostate|March 14, 2022
Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancerEmmanuel S Antonarakis, Marni Tierno, Virginia Fisher, et al.
BMC Genetics|September 27, 2018
The challenge of detecting genotype-by-methylation interaction: GAW20Mariza de Andrade, E Warwick Daw, Aldi T Kraja, et al.
JCO Clinical Cancer Informatics|March 17, 2022
Natural History of Human Epidermal Growth Factor Receptor 2-Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical PracticeCarsten Schröder, Craig Gower-Page, Irmarie Reyes-Rivera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast CarcinomaHope S Rugo, Kira Raskina, Alexa B Schrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2022
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate CancerUmang Swami, Ryon P Graf, Roberto H Nussenzveig, et al.
European Urology|October 30, 2021
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate CancerRyon P Graf, Virginia Fisher, Joaquin Mateo, et al.
JAMA Network Open|March 31, 2022
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate CancerRyon P Graf, Virginia Fisher, Janick Weberpals, et al.
Cancer Discovery|October 31, 2020
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor ResponseMeagan Montesion, Karthikeyan Murugesan, Dexter X Jin, et al.
HGG Advances|December 26, 2022
Whole-exome sequence analysis of anthropometric traits illustrates challenges in identifying effects of rare genetic variantsKristin L Young, Virginia Fisher, Xuan Deng, et al.
Frontiers in Genetics|November 29, 2023
Gene-educational attainment interactions in a multi-population genome-wide meta-analysis identify novel lipid lociLisa de las Fuentes, Karen L Schwander, Michael R Brown, et al.
Pageof 3